当前位置：   首页 > 需求大厅

1.符合国家颁布的标准：WS-039（X-34）-92 2.需求量：100g   [更多]

交易模式： 单人中标 赏金分配： $28,000，已选0个，还需要1个。截止日期：2014年12月12日 已有提案：19件，发布时间：2014年11月12日 具体要求： 神经退化性疾病影响到数以百万计的世界各地的人们，它给病人和他们的照顾者经济上和情感上造成了巨大负担。尽管这些疾病的发病机制尚不清楚，但一些相关治疗仍是可用的，比如要让药物直接作用于中枢神经系统的病灶，药物传递和分散到脑部的过程却是关键。从临床前后的数据表明，在脑脊髓液（CSF）中的药物浓度可以被用作一个相当精确的指示剂来检查发生在大脑中的变化。研究人员想要找到一种解决办法，即为精确标测量在脑或脑脊液特异性蛋白质的方法。 神经变性疾病时，在脑和脊髓的神经元开始发生恶化和功能异常。这些疾病主要发生在人们中老年的生活：随着年龄增长产生的疾病，如阿尔茨海默氏症，帕金森氏症和神经多发性硬化症发病率的上升。目前神经退化性疾病的治疗取得了一些进展，改善了患者的生活质量，但是还没有治愈。为了提高临床前测试的可预测性和在临床测试的成功可能性，所述研究人员希望找出一种用于在脑和/或脑脊液中特定蛋白的检测。这一悬赏只需要一个书面建议。 以下几条信息必须同时满足: 1. 必须在2014年12月12日下午11时59分（美国东部时间）收到，逾期的投标概不受理。只需要提案人一个书面建议提交。解决方领取奖金的同时，必须将其独有的知识产权（IP）的权利转让给举办方。 2.这个悬赏任务是必须找出一种用于在脑和/或脑脊液中特定蛋白的检测方法，可在临床前后测试中判断出这些神经变性疾病。 3、在以下网站进行投稿：Protein Detection in Brain and Cerebrospinal Fluid | InnoCentive Challenge https://www.innocentive.com/ar/challenge/9933525   [更多]

我们体内以分泌胰岛素来维持胰岛细胞血糖水平和体内平衡。而糖尿病患者的胰岛细胞是缺乏或无效的。没有足够活性的胰岛素，糖尿病患者就无法控制血糖。胰岛移植是一种治疗策略,糖尿病患者需要胰岛素注射来控制他们的疾病，减轻或根除症状。阿斯利康正在寻找一个简单的装置将人类胰岛移植出来，来检测药物的性能。 具体如下网站，https://www.innocentive.com/ar/challenge/9933735 Pancreatic islet beta-cells sense blood sugar levels and secrete insulin to maintain homeostasis. In patients with diabetes, islet beta-cells are either lacking or ineffective. Islet transplantation is a treatment strategy that allows diabetics to reduce or eliminate the need for insulin injections to control their disease. AstraZeneca is searching for a simple device to transplant human islets to facilitate testing of therapeutic agents. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933735 Challenge Overview Diabetes is a disease of the pancreatic islet cells. Of the four cell types, insulin-producing beta-cells are the most abundant. Without adequate levels of insulin, diabetes patients have difficulty controlling their blood sugar. One alternative to self-administration of medicine is islet transplantation. The procedure involves an infusion of isolated donor islets into the patient. If the graft is accepted, these islets will function to regulate blood glucose levels through the production of insulin. AstraZeneca is searching for a simple device for the transplantation and subsequent retrieval of human islets to support in vivo testing of therapeutic agents. ABOUT THE SEEKER AstraZeneca is a global, research-based, biopharmaceutical company with a focus on five key therapeutic areas: 1) cardiovascular & metabolic diseases, 2) oncology, 3) respiratory, inflammation & autoimmunity, 4) neuroscience, and 5) infection. As an innovation-driven, research organization, AstraZeneca recognizes that great ideas come from many sources. Open innovation is an avenue by which ideas can be shared and AstraZeneca recently launched a pavilion to further its commitment to facilitate the advancement of pharmaceutical   [更多]

药物代谢酶的过程中，肝脏是主要负责将药物基质脂溶性化合物转化为水溶性代谢物，可以很容易地通过肾脏排泄的。偶尔，这些代谢产物也会不恰当地和血蛋白结合，从而导致药物的不良反应。阿斯利康希望寻找一种定量测定共价结合细胞蛋白质的新方法。具体的链接请看下面： https://www.innocentive.com/ar/challenge/9933662 AWARD: $25,000 USD | DEADLINE: 3/16/15 | ACTIVE SOLVERS: 74 | POSTED: 1/16/15 Drug metabolism is the enzymatic process by which the body modifies pharmaceutical substrates. The liver is primarily responsible for reactions which convert lipid-soluble compounds into water-soluble metabolites that can easily be excreted by the kidney. Occasionally, these metabolites exhibit chemically reactivity towards host proteins, leading to inappropriate binding that may result in adverse drug reactions. AstraZeneca desires an innovative approach for the quantitative measurement of covalent binding to cellular proteins. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933662 Challenge Overview When new medicines are introduced to the market, not only does the drug need to have a proven therapeutic benefit, but it also must possess an acceptable safety profile. To this end, drug development focuses on minimizing adverse drug reactions (ADRs) and idiosyncratic drug toxicities. ADRs are a major complication of drug therapy and come as a result of drug accumulation and/or the formation of chemically reactive metabolites (CRMs). Formation of CRMs within a cell poses an undesirable chemical liability and for this reason, AstraZeneca desires an innovative approach for the quantitative measurement of covalent binding of metabolites to cellular proteins. ABOUT THE SEEKER AstraZeneca is a global, research-based, biopharmaceutical company with a focus on five key therapeutic areas: 1) cardiovascular & metabolic diseases, 2) oncology, 3) respiratory, inflammation & autoimmunity, 4) neuroscience, and 5) infection. As an innovation-driven, research organization, AstraZeneca recognizes that great ideas come from many sources. Open innovation is an   [更多]

设备应能至少每分钟测量血含量两次，连续测量时间至少60分钟。探头小巧并方便弯曲，准确度：设备必须能够衡量的范围为0 - 1.25毫升的血（稀释在大约15 - 30毫升的盐水中），精度要测准大约6µl的血（稀释在大约15 - 30毫升的盐水中）。 具体如下：https://www.innocentive.com/ar/challenge/9933690 The Seeker desires a device to continuously and/or repeatedly measure the amount of blood in a volume of saline. The device should be capable of measuring at least twice per minute for at least 60 minutes. This is a Reduction-to-Practice Challenge that requires a written proposal, experimental proof-of-concept data, and prototype delivery if requested Source: InnoCentive Challenge ID: 9933690 Challenge Overview The Seeker is looking for a device to continuously measure blood content in a small volume of saline. Blood is introduced continuously through a thin, flexible probe placed in the container of saline and the device must be able to measure the overall blood content in the container at least twice per minute for at least 60 minutes. The device must be able to measure over the range of 0 – 1.25 ml of blood in approximately 15 – 30 ml of saline with an accuracy of approximately 6 µl of blood. Only minimal stirring is allowed, thus devices should not rely on an assumption of uniform mixing of the blood in the saline solution. The rate of blood introduction may vary significantly, and may start and stop numerous times. The submission to the Challenge should include the following: The detailed description of the proposed Solution addressing specific Solution Requirements presented in the Detailed Description of the Challenge. This description should be accompanied by a well-articulated rationale supported by literature/patent precedents. Experimental proof-of-concept data obtained as outlined in the Detailed Description of the Challenge (and delivery of a prototype if requested by the Seeker).   [更多]

我们需要设计自动崩解控制器用于靶向给药。自动崩解控制器，一旦触发，应该可以在温和条件(生理)下使药物分子的释放并激活。这个我们可以参考数量有限的文献中描述“self-immolative”（自动分解或自毁）连接器，但我们提出的自动崩解控制器不是这样的装置。具体链接为https://www.innocentive.com/ar/challenge/9933733，具体如下： Design of A Self-Cleaving Linker For Targeted Drug Delivery TAGS: Physical Sciences, Novel Molecules, Chemistry, Life Sciences, Theoretical-IP Transfer AWARD: $25,000 USD | DEADLINE: 4/27/15 | ACTIVE SOLVERS: 165 | POSTED: 3/26/15 The Seeker desires the design of a novel self-cleaving linker for use in targeted drug delivery. The self-cleaving linker, once triggered, should allow for the release of molecule(s) of interest under mild (physiological) conditions. A limited number of “self-immolative” linkers are well described in the literature and are specifically excluded from this Challenge. The Seeker specifically encourages synthetic chemists to consider this Challenge even if they do not have medicinal chemistry knowledge. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933733 Challenge Overview The Seeker desires the design of a novel self-cleaving linker for use in targeted drug delivery. The self-cleaving linker, once triggered, should allow for the release of molecule(s) of interest under mild (physiological) conditions. A limited number of such “self-immolative” linkers, based upon an elimination to generate a quinone methide, or utilizing a 5 or 6 member ring cyclization, are well described in the literature and are specifically excluded from this Challenge. The Seeker specifically encourages synthetic chemists to consider this Challenge even if they do not have medicinal chemistry knowledge. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. To receive an award, the Solvers will have to transfer to the Seeker their exclusive Intellectual Property   [更多]

重性抑郁障碍（MDD）是一种使人衰弱的精神障碍，在美国约有20000000流行病例。然而不同的抗抑郁药可用于治疗不同的抑郁症，，约50%的抑郁症患者的初始治疗结果不理想。最近有证据表明，在发病的几个小时内氯胺酮给药治疗难治性抑郁症已经显著有所改善。勃林格殷格翰公司寻找氯胺酮在人体中反应和持续的抗抑郁作用的机理。 Boehringer Ingelheim Challenge: Understanding the Antidepressant Effect of Ketamine TAGS: Nature, Chemistry, Life Sciences, Ideation AWARD: $21,000 USD | DEADLINE: 1/15/15 | ACTIVE SOLVERS: 20 | POSTED: 12/15/14 1. The Challenge and qualification for the award Major depressive disorder (MDD) is a debilitating psychiatric disorder with about 20 million prevalent cases in the United States. Various antidepressants are available for treatment of patients suffering from MDD, however, about 50% of MDD patients do not respond adequately to initial treatments. Recent evidence shows that ketamine administered to patients with treatment resistant depression has resulted in marked improvement within hours of treatment. Boehringer Ingelheim (the Seeker) desires a working hypothesis for ketamine’s mechanism of action and sustained antidepressant effect. The submitted solutions will be considered for the award. There will be a guaranteed award for at least one submitted solution. The total payout will be $21,000, with at least one award being no smaller than $12,000 and no award being smaller than $3,000. 2. Additional application for Research Funding In addition to consideration for the award for the submitted Solutions, Solvers with appropriate qualifications and expertise having access to a suitable research laboratory and equipment can apply for research funding (“Research Funding”) to execute a research plan that is proposed in the Solution. The requested funding should not exceed a funding period of 2 years and a total budget of $200,000. The selection of candidates for Research Funding will be conducted after completion of this Challenge, and will require the submission of additional information. The decision to fund research will be at the discretion of the Seeker.   [更多]

　　因公司发展需要，急需甲钴胺的大生产或中试后的生产工艺，要求能批量得到合格的产品，符合国家药品标准，步骤在两步之内，最好从VB12开始做，价格好商量，公司和个人合作都可!   [更多]

寻求常温结晶法生产高稳定性过碳酸钠 工业纯碱和双氧水加入内稳定剂，温度在15~30℃之间反应生成过碳酸钠。 目前工艺难度： (1)产品圆整度、硬度不好; (2)收率低; (3)稳定性差。急需解决。 预期达到技术、经济指标： 1、产品外观颗粒大小均匀、圆整度、硬度好。 2、稳定性等指标符合行业标准。 3、收率：碱0.72kg/kg产品，H2O2：1.2kg(27.5%)/kg产品。   [更多]

一、糠醛两步法生产工艺研究 糠醛是一种重要的化工原料，具有广阔的应用前景。目前，我公司生产糠醛主要采用一步法生产，一步法蒸汽消耗量大，一般吨醛消耗蒸汽18～25t，且该法糠醛收率最高只有6O%，原料得不到充分利用，并产生大量的废渣。随着糠醛工业的发展，以及原料综合利用要求的提高，发展两步法糠醛生产工艺，分离原料中的纤维素和半纤维素并分别加以利用，是糠醛工业的必然发展趋势，但是两步法工艺较为复杂，设备投资高，第二步脱水工艺条件不十分成熟， 因此公司希望可以与其他单位合作，共同研究糠醛两步法生产工艺，以达到提高收率，抑制生成的糠醛发生副反应，并提高原料综合利用率。 二、糠醛生产中纤维素的深度开发 1、生物基材料---糠醛生产中纤维素的深度开发; 2、二氧化硫脲漂白高岭土的应用技术; 3、二氧化硫脲在靛蓝印染上的应用 三、糠醛渣制造生物柴油深度开发研究 我公司水解釜排出来的废渣，经过锅炉烟道气流化干燥后直接进入锅炉去燃烧。锅炉燃烧所产生的烟道气经旋风除尘，湿法脱硫，硫化干燥水解废渣，最后再进入高空烟囱排放。但是由于糠醛渣含水率高，发热值低，燃烧处理时利用率较低。因此，糠醛渣深度开发、有效利用成为糠醛生产企业的一大难题。 由于生物柴油具有优良的环保特性，良好的燃料性能，并具有可再生性，开发糠醛渣制造生物柴油新技术，解决企业糠醛渣废固利用，增加效益，提升企业技术水平和经济效益。 因此公司希望可以与其他单位合作，共同研发布   [更多]